NASDAQ:ATRA

Atara Biotherapeutics Stock News

etoro logo Buy ATRA
*Your capital is at risk
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics
Maverick Capital Ltd. increased its holdings in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 4.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange C
Ohio Gov. Mike DeWine signed the CARES Act statewide distribution into law on Friday (June 19). with Shaker City Council setting up the required Local Coronavirus Fund three days later.
Wellington Management Group LLP grew its position in Centurylink Inc (NYSE:CTL) by 599.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission
Transport secretary intervenes over fate of 1,500 people stranded on five vessels
Equities analysts predict that Centurylink Inc (NYSE:CTL) will announce earnings of $0.33 per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates
Alliancebernstein L.P. lifted its holdings in shares of Centurylink Inc (NYSE:CTL) by 5.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm
CMV scrambles for funding after failing to secure £25m loan from Barclays
Orca Bio raised $192 million from Lightspeed Venture Partners and an unnamed investor for its experimental cell therapy platform.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including soli
Cruise firm Cruise and Maritime Voyages (CMV) is in a race against time to secure emergency funding after the coronavirus crisis left it struggling.
Stock analysts at HC Wainwright assumed coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research report issued to clients and investors on Monday, Marketbeat reports. The firm set a “
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatment
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE